The Current Ratio as of November 2024 (TTM) for Kezar Life Sciences, Inc. (KZR) is 9.58

According to Kezar Life Sciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.58. This represents a change of -17.68% compared to the average of 11.64 of the last 4 quarters.

Kezar Life Sciences, Inc. (KZR) Historical Current Ratio (quarterly & annually)

How has KZR Current Ratio performed in the past?

The mean historical Current Ratio of Kezar Life Sciences, Inc. over the last ten years is 22.96. The current 9.58 Current Ratio has changed 4.07% with respect to the historical average. Over the past ten years (40 quarters), KZR's Current Ratio was at its highest in in the June 2022 quarter at 39.64. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Kezar Life Sciences, Inc. (KZR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Kezar Life Sciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kezar Life Sciences, Inc. (KZR) Average Current Ratio

How has KZR Current Ratio performed in the past?

The current Current Ratio of Kezar Life Sciences, Inc. (KZR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Kezar Life Sciences, Inc. (KZR) Current Ratio vs. Peers

How is KZR’s Current Ratio compared to its peers?

Kezar Life Sciences, Inc.’s Current Ratio is less than Century Therapeutics, Inc. (10.62), less than Mineralys Therapeutics, Inc. (11.20), less than Nkarta, Inc. (15.91), greater than NGM Biopharmaceuticals, Inc. (7.79), greater than Surrozen, Inc. (6.96), greater than Bolt Biotherapeutics, Inc. (4.28), less than Larimar Therapeutics, Inc. (13.10), less than Keros Therapeutics, Inc. (20.37), less than Lyell Immunopharma, Inc. (16.19), less than Cullinan Oncology, Inc. (28.87), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Theseus Pharmaceuticals, Inc. (29.93), less than Revolution Medicines, Inc. (15.42), greater than Foghorn Therapeutics Inc. (5.69), greater than Shattuck Labs, Inc. (7.62), greater than Kymera Therapeutics, Inc. (8.55), greater than Nurix Therapeutics, Inc. (5.28), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67),

Build a custom stock screener for Kezar Life Sciences, Inc. (KZR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kezar Life Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kezar Life Sciences, Inc. (KZR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kezar Life Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.